LabCorp Launches Next Generation Sequencing Assay for Familial Cardiac Disease

  LabCorp Launches Next Generation Sequencing Assay for Familial Cardiac

  New technology compliments disease focused approach to diagnostic testing

Business Wire

BURLINGTON, N.C. -- February 25, 2013

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) today
announced it has launched its clinical next generation sequencing assay,
GeneSeq®: Cardio for genetic causes of familial cardiac disease.

Familial cardiac diseases are associated with up to 80% of cases of sudden
cardiac death in young patients. Identification of individuals with pathogenic
mutations in genes associated with cardiac disease may allow timely initiation
of screening and treatment that may help prevent myocardial infarction,
stroke, and sudden cardiac death.

“GeneSeq®: Cardio is a useful tool to identify individuals that may require
regular cardiac screening, lifestyle changes, or clinical intervention to
prevent the progression of cardiac disease and secondary complications,” said
Dr. Mark Brecher, LabCorp’s Chief Medical Officer. “This assay complements our
broad testing menu and enhanced reporting for cardiovascular disease.”

“This next generation sequencing assay is a significant milestone, as LabCorp
embraces new technologies and bioinformatics to further our ability to service
patients and physicians,” said David P. King, Chairman and Chief Executive
Officer. “We will continue to launch next generation assays to provide the
most comprehensive, cost-effective diagnostic tools for multiple disease

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.7 billion in 2012, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its LabCorp Specialty Testing
Group: The Center for Molecular Biology and Pathology, National Genetics
Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing,
Litholink Corporation, Integrated Genetics, Integrated Oncology, DIANON
Systems, Inc., Monogram Biosciences, Inc., Colorado Coagulation, and Endocrine
Sciences. LabCorp conducts clinical trials testing through its LabCorp
Clinical Trials division. LabCorp clients include physicians, government
agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our organization, visit our Web
site at:

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2011, and subsequent SEC filings, and will be
available in the Company’s Form 10-K for the year ended December 31, 2012,
when filed.


Laboratory Corporation of America^® Holdings
Stephen Anderson, 336-436-5076
Press spacebar to pause and continue. Press esc to stop.